

13 February 2023

The Listing Department  
National Stock Exchange of India Limited  
Exchange Plaza C-1, Block G  
Bandra Kurla Complex  
Bandra (East)  
Mumbai - 400051

**Symbol: BANKA**

**Sub: Statement of Deviation(s) or Variation(s) under Regulation 32(1) of SEBI (LODR) Regulations, 2015 for the quarter ended 31 December 2022**

Dear Sir/Madam,

With reference to the above-cited subject, please find enclosed herewith the statement of deviation(s) or variation(s) under Regulation 32(1) of SEBI (LODR) Regulations, 2015 for the quarter and year ended 31 December 2022.

This is for your information and necessary records.

Thank you.

**For Banka BioLoo Limited**

**T V Rama Krishna**  
**CFO & Executive Director**  
**DIN 07977695**

## **Statement of Deviation(s) or Variation(s) under Regulation 32(1) of SEBI (LODR) Regulations, 2015**

In reference to the compliance under Regulation 32(1)(a) & (b) of SEBI (LODR) Regulations, 2015, as required under regulation 32(8) of SEBI (LODR) Regulations, 2015, the Company hereby submits to National Stock Exchange, statement of deviation(s) or variation(s) for the quarter and year ended 31 December 2022.

**a) Indicating deviations, if any, in the use of proceeds from the objects stated in the offer document or explanatory statement to the notice for the general meeting, as applicable:**

We, hereby, inform you that there was no deviation in the utilisation of the proceeds of the public issue from the objects stated in the prospectus of the issue, as required under regulation 32(1)(a) of SEBI (LODR) Regulations, 2015.

**b) Indicating category-wise variation (capital expenditure, sales and marketing, working capital etc.) between projected utilization of funds made by it in its offer document or explanatory statement to the notice for the general meeting, as applicable, and the actual utilisation of funds:**

We, hereby, inform that there has been no variation in the use of the proceeds from the objects stated in the prospectus dated 23 January 2018, or explanatory statement to the notice of the Extra-Ordinary Meeting dated 16 November 2017, issued for initial public offering of securities, as per Regulation 32(1)(b) of SEBI (LODR) Regulations, 2015.

Thank you.

**For Banka BioLoo Limited**

**T V Rama Krishna  
CFO & Executive Director  
DIN 07977695**

**Statement of Deviation/Variation in utilisation of funds raised**

Name of listed entity	Banka BioLoo Limited					
Mode of Fund Raising	Public Issue					
Date of Raising Funds	5 February 2018 to 16 February 2018					
Amount Raised (INR in Lakhs)	1,262.70					
Report filed for Quarter ended	31 December 2022					
Monitoring Agency	<b>Applicable/ Not Applicable</b>					
Monitoring Agency Name, if applicable	Not Applicable					
Is there a Deviation/ Variation in use of funds raised	<b>Yes/No</b>					
If yes, whether the same is pursuant to change in terms of a contract or objects, which was approved by the shareholders	Not Applicable					
If Yes, Date of shareholder Approval	Not Applicable					
Explanation for the Deviation/ Variation	Not Applicable					
Comments of the Audit Committee after review	Not Applicable					
Comments of the auditors, if any	Not Applicable					
Objects for which funds have been raised and where there has been a deviation, in the following table (INR in Lakhs)						
Original Objects	Modified Objects, if any	Original Allocation	Modified Allocation, if any	Funds Utilised	Amount of Deviation /variation for the quarter according to applicable object	Remarks if any
Long-Term Working Capital Requirement	NA	797.88	NA	797.88	NA	No Deviation
General Corporate Purpose	NA	231.62	NA	231.62	NA	No Deviation
Issue Related Expenses-Company portion	NA	61.10	NA	61.08	NA	No Deviation
Capital expenditure at existing inoculum generation plant at Aler	NA	75.21	NA	75.21	NA	No Deviation
Capital expenditure at proposed new unit at Ibrahimpatnam	NA	96.89	NA	26.42	NA	No Deviation
<i>Deviation or variation could mean:</i>						
<i>(a) Deviation in the objects or purposes for which the funds have been raised or</i>						
<i>(b) Deviation in the amount of funds actually utilized as against what was originally disclosed or</i>						
<i>(c) Change in terms of a contract referred to in the fund-raising document i.e., prospectus, letter of offer, etc.</i>						

**For Banka BioLoo Limited**

**Tadepalli Venkata Rama Krishna**  
**CFO & Executive Director**  
**DIN: 07977695**

Date: 13 February 2023

Place: Hyderabad